Patents by Inventor Steven M. Ruben
Steven M. Ruben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170096472Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: December 16, 2016Publication date: April 6, 2017Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Patent number: 9403905Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: May 15, 2014Date of Patent: August 2, 2016Assignee: HUMAN GENOME SCIENCES, INC.Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
-
Publication number: 20160152687Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: February 11, 2016Publication date: June 2, 2016Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Patent number: 9296809Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: August 5, 2015Date of Patent: March 29, 2016Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Patent number: 9221896Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: February 2, 2015Date of Patent: December 29, 2015Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20150329619Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: August 5, 2015Publication date: November 19, 2015Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Patent number: 9187548Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.Type: GrantFiled: January 23, 2012Date of Patent: November 17, 2015Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Steven C. Barash, Gil H. Choi, Tristan Vaughan, David Hilbert
-
Publication number: 20150203568Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: February 2, 2015Publication date: July 23, 2015Inventors: CRAIG A. ROSEN, WILLIAM A. HASELTINE, STEVEN M. RUBEN
-
Patent number: 8993517Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: June 27, 2013Date of Patent: March 31, 2015Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20140342405Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: ApplicationFiled: May 15, 2014Publication date: November 20, 2014Applicant: Human Genome Sciences, Inc.Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
-
Publication number: 20140328794Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.Type: ApplicationFiled: July 18, 2013Publication date: November 6, 2014Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20140303077Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: June 27, 2013Publication date: October 9, 2014Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Patent number: 8784809Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: January 24, 2013Date of Patent: July 22, 2014Assignee: Human Genome Sciences, Inc.Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
-
Publication number: 20140179596Abstract: Provided herein are albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins and vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins and using these nucleic acids, vectors, and/or host cells also are provided. Further described are pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: August 13, 2013Publication date: June 26, 2014Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Steven M. Ruben, Olivier Blondel
-
Publication number: 20130309232Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: ApplicationFiled: January 24, 2013Publication date: November 21, 2013Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
-
Patent number: 8518389Abstract: The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR17. TR17 polypeptides are also provided as anti TR17 antibodies and vectors, host cells and recombinant methods for producing the same. The invention further relates to methods of killing cells using the antibodies of the invention.Type: GrantFiled: December 16, 2008Date of Patent: August 27, 2013Assignee: Human Genome SciencesInventors: Steven M. Ruben, Kevin P. Baker
-
Patent number: 8513189Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: April 1, 2011Date of Patent: August 20, 2013Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20130203164Abstract: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions (such as immune, cardiovascular, cancer, and other proliferative diseases, disorders, and/or conditions) related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.Type: ApplicationFiled: March 22, 2013Publication date: August 8, 2013Applicant: Human Genome Sciences, Inc.Inventors: Craig A. ROSEN, Steven M. Ruben
-
Publication number: 20130157933Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.Type: ApplicationFiled: April 1, 2011Publication date: June 20, 2013Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20130150296Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: April 1, 2011Publication date: June 13, 2013Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben